All News

2020

June

Media Release / Jun 11, 2020

US FDA approves updated Novartis Beovu® label, to include additional safety information

Read More
Media Release / Jun 05, 2020

Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma

Read More
Media Release / Jun 04, 2020

Novartis PREVENT data show Cosentyx® helps patients realize early and lasting relief in axial spondyloarthritis

Read More
Pride 2020
Featured News / Jun 03, 2020

Pride @ Novartis 2020 – inspired to make a difference

Together in spirit. Find out how our associates all over the world are joining together to make a difference as we celebrate Pride 2020.

Read More
Media Release / Jun 02, 2020

Novartis provides update on FDA review of ofatumumab, a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis

Read More
Featured News / Jun 01, 2020

European Patient Innovation Summit publishes call for action to ensure greater patient involvement in digital health solution development

EPIS participants call for all stakeholders to ensure the patient voice is at the heart of the development of digital health solutions

Read More

May

Media Release / May 29, 2020

Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery

Read More
Media Release / May 29, 2020

Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation

Read More
Illustration of the coronavirus created at the Centers for Disease Control and Prevention (CDC)
Featured News / May 28, 2020

Coronavirus (COVID-19) news feed

Read More
Media Release / May 28, 2020

Novartis data highlight benefit of early treatment initiation in patients with secondary progressive multiple sclerosis (SPMS)

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More